Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
biochem_4c03_2021_winter [2021/02/09 12:04] alidoosa |
biochem_4c03_2021_winter [2022/04/08 15:51] (current) yang |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| [[Example Page]] | [[Example Page]] | ||
| - | [[Group_1_TA_Agata_Kieliszek "Immune responses against SARS-CoV-2"]]; | + | [[Group_1_TA_Agata_Kieliszek_Presentation_1 "Immune responses against SARS-CoV-2"]]; |
| - | [[Group_1_TA_Agata_Kieliszek "Immune responses against SARS-CoV-2" - Presentation 1]]; | + | [[Group_1_TA_Agata_Kieliszek_Presentation_2 "Immune responses against SARS-CoV-2"]]; |
| [[Group_2_TA_Sansi_Xing "Pathogenesis and transmission of SARS-CoV-2"]]; | [[Group_2_TA_Sansi_Xing "Pathogenesis and transmission of SARS-CoV-2"]]; | ||
| + | |||
| + | [[Group_2_TA_Sansi_Xing "Transgenic Mouse model of SARS-CoV-2 pathogenesis and transmission"]]; | ||
| [[Group_3_TA_Agata_Kieliszek "Therapeutic targeting of SARS-CoV-2"]]; | [[Group_3_TA_Agata_Kieliszek "Therapeutic targeting of SARS-CoV-2"]]; | ||
| + | |||
| + | [[Group_3_TA_Agata_Kieliszek_Presentation_2 "Therapeutic Targeting of SARS-CoV-2"]]; | ||
| [[Group_4_TA_Sansi_Xing "Vaccine treatment of SARS-CoV-2"]]; | [[Group_4_TA_Sansi_Xing "Vaccine treatment of SARS-CoV-2"]]; | ||
| + | |||
| + | [[Group_4_TA_Sansi_Xing_Presentation_2 "Vaccine treatment of SARS-CoV-2"]]; | ||
| [[Group_5_TA_Agata_Kieliszek "Stem cell models and/or therapies for SARS-CoV-2"]]; | [[Group_5_TA_Agata_Kieliszek "Stem cell models and/or therapies for SARS-CoV-2"]]; | ||
| + | |||
| + | [[Group_5_TA_Agata_Kieliszek_Presentation_2 "Stem cell models and/or therapies for SARS-CoV-2"]]; | ||
| [[Group_6_TA_Sansi_Xing "Diagnostics of SARS-CoV-2"]] | [[Group_6_TA_Sansi_Xing "Diagnostics of SARS-CoV-2"]] | ||
| + | [[Group_6_TA_Sansi_Xing_Presentation_2 "CRISPR-Cas12-based detection of SARS-CoV-2"]] | ||
| + | {{:4c03_2021_winter_term.png?200|}} | ||
